New Mexico Educational Retirement Board cut its stake in Regeneron Pharmaceuticals Inc (NASDAQ:REGN) by 1.5% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 6,400 shares of the biopharmaceutical company’s stock after selling 100 shares during the quarter. New Mexico Educational Retirement Board’s holdings in Regeneron Pharmaceuticals were worth $2,003,000 as of its most recent filing with the Securities and Exchange Commission.
Other institutional investors have also bought and sold shares of the company. Smithfield Trust Co. acquired a new position in Regeneron Pharmaceuticals during the first quarter worth $27,000. Citizens Financial Group Inc RI acquired a new position in Regeneron Pharmaceuticals during the first quarter worth $30,000. Accurate Investment Solutions Inc. acquired a new position in Regeneron Pharmaceuticals during the second quarter worth $31,000. Thor Advisors LLC acquired a new position in Regeneron Pharmaceuticals during the first quarter worth $32,000. Finally, Coastal Capital Group Inc. acquired a new position in Regeneron Pharmaceuticals during the second quarter worth $38,000. 65.85% of the stock is currently owned by hedge funds and other institutional investors.
Shares of NASDAQ REGN traded up $0.45 during mid-day trading on Friday, hitting $295.47. The company had a trading volume of 11,151 shares, compared to its average volume of 723,588. The company has a debt-to-equity ratio of 0.07, a current ratio of 3.88 and a quick ratio of 3.11. The business’s 50-day simple moving average is $301.89 and its 200-day simple moving average is $347.72. Regeneron Pharmaceuticals Inc has a 12 month low of $287.66 and a 12 month high of $442.00. The firm has a market cap of $32.29 billion, a P/E ratio of 14.79, a PEG ratio of 1.35 and a beta of 1.15.
A number of equities research analysts have issued reports on REGN shares. Morgan Stanley decreased their price target on shares of Regeneron Pharmaceuticals from $420.00 to $389.00 and set an “equal weight” rating for the company in a report on Wednesday, May 8th. TheStreet cut shares of Regeneron Pharmaceuticals from a “b-” rating to a “c+” rating in a report on Wednesday, June 5th. Leerink Swann set a $453.00 price target on shares of Regeneron Pharmaceuticals and gave the company a “buy” rating in a report on Tuesday, June 11th. BidaskClub upgraded shares of Regeneron Pharmaceuticals from a “strong sell” rating to a “sell” rating in a report on Friday, July 19th. Finally, UBS Group decreased their price target on shares of Regeneron Pharmaceuticals from $480.00 to $440.00 and set a “buy” rating for the company in a report on Wednesday, May 8th. Two research analysts have rated the stock with a sell rating, twelve have assigned a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the stock. The company currently has a consensus rating of “Hold” and a consensus target price of $398.25.
Regeneron Pharmaceuticals Company Profile
Regeneron Pharmaceuticals, Inc, a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for treating various medical conditions worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema (DME); myopic choroidal neovascularization; and diabetic retinopathy in patients with DME, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion.
Featured Story: What are gap-down stocks?
Want to see what other hedge funds are holding REGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Regeneron Pharmaceuticals Inc (NASDAQ:REGN).
Receive News & Ratings for Regeneron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.